Geron Corporation - Common Stock (NQ:GERN)

1.145 +0.025 (+2.23%)

Delayed Quote Updated: 10:51 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

November 02, 2023

From Geron Corporation

Via Business Wire

Geron Earnings Preview ↗

November 01, 2023

Via Benzinga

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

October 26, 2023

From Geron Corporation

Via Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 19, 2023

From Geron Corporation

Via Business Wire

Geron (GERN) Q2 2023 Earnings Call Transcript ↗

August 03, 2023

GERN earnings call for the period ending June 30, 2023.

Via The Motley Fool

7 Must-Own Small-Cap Stocks That Could Outperform the Market ↗

October 08, 2023

If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you.

Via InvestorPlace

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

September 29, 2023

From Geron Corporation

Via Business Wire

Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs ↗

September 12, 2023

Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p

Via Benzinga

Why Is Geron (GERN) Stock Up Today? ↗

September 12, 2023

Geron (GERN) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares from Goldman Sachs.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗

September 12, 2023

Via Benzinga

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

September 11, 2023

From Geron Corporation

Via Business Wire

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting

September 07, 2023

From Geron Corporation

Via Business Wire

Geron to Participate in the Baird 2023 Global Healthcare Conference

September 05, 2023

From Geron Corporation

Via Business Wire

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

August 22, 2023

From Geron Corporation

Via Business Wire

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

August 21, 2023

From Geron Corporation

Via Business Wire

Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 22, 2023

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.

Via Benzinga

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2023

From Geron Corporation

Via Business Wire

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

August 03, 2023

From Geron Corporation

Via Business Wire

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

July 27, 2023

From Geron Corporation

Via Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2023

From Geron Corporation

Via Business Wire

Thoughts For Thursday: Back From The Holiday With Caution ↗

July 06, 2023

Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China.

Via Talk Markets

Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

June 29, 2023

From Geron Corporation

Via Business Wire

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now ↗

June 29, 2023

With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.

Via InvestorPlace

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 22, 2023

From Geron Corporation

Via Business Wire

What's Going On With Geron Stock Today ↗

June 20, 2023

Geron Corporation (NASDAQ: GERN) submitted a marketing application with the FDA seeking approval for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to...

Via Benzinga

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

June 20, 2023

From Geron Corporation

Via Business Wire

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

June 13, 2023

From Geron Corporation

Via Business Wire

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

June 12, 2023

From Geron Corporation

Via Business Wire

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

June 07, 2023

From Geron Corporation

Via Business Wire

Geron to Host Virtual Investor Event on June 14, 2023

June 06, 2023

From Geron Corporation

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.